argenx SE ARGX
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +6.17%
- 1 year
- +8.84%
- Open
- 896.79
- Prev close
- 897.85
- Mkt cap
- 56.15B
- Vol
- 462.45K
- Avg vol
- 346.69K
- EPS
- 28.87
- P/E
- 30.93
- Div yield
- 0.00%
More statistics
- Low
- 890.44
- High
- 916.05
- Forward P/E
- 26.80
- Beta
- -0.04
- Short ratio
- 3.31
- Inst. own
- 46.12%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 25, 2027
- 50-d avg
- 946.51
- 200-d avg
- 854.26
- 1y target
- 1,147.35
5D chart
Events in this range
- Oct 27, 2026Rating: Citigroup · Buy → Buy
Signals (154)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 3:55 PM | 1 day ago |
| SMA: Bullish | Oct 30, 3:45 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 3:45 PM | 1 day ago |
| SMA: Bearish | Oct 30, 3:40 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 3:40 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 3:35 PM | 1 day ago |
| SMA: Bullish | Oct 30, 3:30 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 2:50 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 2:45 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 2:40 PM | 1 day ago |
| SMA: Bearish | Oct 30, 2:30 PM | 1 day ago |
| SMA: Bullish | Oct 30, 2:25 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 2:25 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 2:20 PM | 1 day ago |
| SMA: Bearish | Oct 30, 2:10 PM | 1 day ago |
| SMA: Bullish | Oct 30, 2:00 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 2:00 PM | 1 day ago |
| SMA: Bearish | Oct 30, 1:35 PM | 1 day ago |
| SMA: Bullish | Oct 30, 1:25 PM | 1 day ago |
| SMA: Bearish | Oct 30, 1:15 PM | 1 day ago |
| SMA: Bullish | Oct 30, 1:10 PM | 1 day ago |
| SMA: Bearish | Oct 30, 1:05 PM | 1 day ago |
| SMA: Bullish | Oct 30, 1:00 PM | 1 day ago |
| SMA: Bearish | Oct 30, 12:10 PM | 1 day ago |
| SMA: Bearish | Oct 30, 12:10 PM | 1 day ago |
| SMA: Bullish | Oct 30, 12:05 PM | 1 day ago |
| SMA: Bullish | Oct 30, 12:05 PM | 1 day ago |
| SMA: Bearish | Oct 30, 11:45 AM | 1 day ago |
| MACD: Sell Signal | Oct 30, 11:30 AM | 1 day ago |
| SMA: Bearish | Oct 30, 11:15 AM | 1 day ago |
| MACD: Buy Signal | Oct 30, 10:45 AM | 1 day ago |
| SMA: Bullish | Oct 30, 10:40 AM | 1 day ago |
| SMA: Bullish | Oct 30, 10:30 AM | 1 day ago |
| SMA: Bearish | Oct 30, 10:15 AM | 1 day ago |
| MACD: Sell Signal | Oct 30, 10:15 AM | 1 day ago |
| SMA: Bearish | Oct 30, 10:00 AM | 1 day ago |
| SMA: Bullish | Oct 30, 9:30 AM | 2 days ago |
| RSI: Overbought | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 29, 4:00 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:45 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:40 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:25 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 3:25 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:20 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:15 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:10 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:10 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:05 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:00 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:00 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:45 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:40 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:35 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 1:35 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:25 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:50 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 12:50 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:45 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:40 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:30 PM | 2 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 2 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:10 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:05 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:55 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:25 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:10 AM | 2 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:25 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:15 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:50 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:40 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:30 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:25 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:15 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:15 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:00 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:55 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:45 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 1:30 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:20 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:15 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:10 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:05 PM | 3 days ago |
| SMA: Bearish | Oct 28, 11:30 AM | 3 days ago |
| SMA: Bullish | Oct 28, 11:25 AM | 3 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 11:05 AM | 3 days ago |
| RSI: Overbought | Oct 28, 10:35 AM | 3 days ago |
| RSI: Overbought | Oct 28, 10:05 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:40 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 4 days ago |
| RSI: Overbought | Oct 27, 3:55 PM | 4 days ago |
| RSI: Overbought | Oct 27, 3:35 PM | 4 days ago |
| RSI: Overbought | Oct 27, 3:20 PM | 4 days ago |
| RSI: Overbought | Oct 27, 3:10 PM | 4 days ago |
| RSI: Overbought | Oct 27, 2:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 2:25 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:15 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:15 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:10 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:05 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:55 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:50 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:45 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:35 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 1:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 1:00 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:25 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 12:25 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 12:10 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 11:55 AM | 4 days ago |
| SMA: Bullish | Oct 27, 11:40 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 11:40 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 11:35 AM | 4 days ago |
| SMA: Bearish | Oct 27, 11:10 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:30 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:10 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 10:10 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 10:05 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:55 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:50 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 9:50 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 9:30 AM | 5 days ago |
| RSI: Oversold | Oct 27, 9:30 AM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:55 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:50 PM | 5 days ago |
| RSI: Oversold | Oct 26, 3:25 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 2:35 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:30 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:25 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:15 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:10 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:45 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:30 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:20 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:05 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:00 PM | 5 days ago |
| SMA: Bearish | Oct 26, 11:50 AM | 5 days ago |
| SMA: Bullish | Oct 26, 11:15 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:25 AM | 5 days ago |
News
3 days ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argenx" or the "Company") (NASDAQ: ARGX). Such investors are advised to contact…
4 days ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE (“argenx” or the “Company”) (NASDAQ: ARGX). Such investors are advised to contact…
-
4 days ago benzinga.com
Citigroup Maintains Buy on argenx, Lowers Price Target to $1232
Citigroup analyst Samantha Semenkow maintains argenx (NASDAQ:ARGX) with a Buy and lowers the price target from $1301 to $1232.
5 days ago benzinga.com
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 12.9% on an annualized basis producing an average annual return of 23.66%. Currently, argenx has a market capitalization of…
-
1 week ago benzinga.com
Morgan Stanley Maintains Overweight on argenx, Raises Price Target to $1190
Morgan Stanley analyst Sean Laaman maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $1140 to $1190.
-
1 week ago benzinga.com
Guggenheim Maintains Buy on argenx, Lowers Price Target to $1120
Guggenheim analyst Yatin Suneja maintains argenx (NASDAQ:ARGX) with a Buy and lowers the price target from $1185 to $1120.
-
1 week ago benzinga.com
Wells Fargo Maintains Overweight on argenx, Lowers Price Target to $1336
Wells Fargo analyst Derek Archila maintains argenx (NASDAQ:ARGX) with a Overweight and lowers the price target from $1356 to $1336.
-
1 week ago benzinga.com
Evercore ISI Group Maintains Outperform on argenx, Raises Price Target to $1090
Evercore ISI Group analyst Gavin Clark-Gartner maintains argenx (NASDAQ:ARGX) with a Outperform and raises the price target from $1078 to $1090.
1 week ago benzinga.com
Procter & Gamble To Rally Over 12%? Here Are 10 Top Analyst Forecasts For Friday
Analysts cut EAT, TTMI and MRTN targets, while raising SPOT, RBLX, S, PG and ARGX; ratings were largely maintained.
-
1 week ago benzinga.com
Baird Maintains Neutral on argenx, Raises Price Target to $861
Baird analyst Colleen Kusy maintains argenx (NASDAQ:ARGX) with a Neutral and raises the price target from $823 to $861.
1 week ago fool.com
argenx: 3 Key Takeaways for Long-Term Investors
Product net sales reached $1.7 billion, growing 54% year over year. Operating profit reached $486 million with a 28% operating margin.
1 week ago defenseworld.net
714 argenex SE $ARGX Shares Bought by Diversify Advisory Services LLC
Diversify Advisory Services LLC lifted its position in shares of argenex SE (NASDAQ: ARGX) by 32.5% during the undefined quarter, according to its most recent filing with the Securities and Exchange…
1 week ago seekingalpha.com
argenx SE (ARGX) Q3 2026 Earnings Call Transcript
argenx SE ( ARGX ) Q3 2026 Earnings Call October 22, 2026 8:30 AM EDT Company Participants Beth DelGiacco Karen Massey - CEO & Executive Director Karl Gubitz - Chief Financial Officer Sandrine…
1 week ago zacks.com
HRMY or ARGX: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and argenex SE (ARGX). But which of these two stocks offers value…
1 week ago marketbeat.com
What argenex (ARGX) Said on Its Q3 Earnings Call
argenex NASDAQ: ARGX reported third-quarter 2026 product net sales of $1.7 billion, up 54% from a year earlier and 13% sequentially, as patient growth in generalized myasthenia gravis, or MG, and…
1 week ago benzinga.com
argenx Q3 2026 Earnings Call Transcript
argenx (NASDAQ:ARGX) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
-
1 week ago benzinga.com
argenx Q3 EPS $7.80 Misses $7.83 Estimate, Sales $1.751B Beat $1.664B Estimate
argenx (NASDAQ:ARGX) reported quarterly earnings of $7.80 per share which missed the analyst consensus estimate of $7.83 by 0.38 percent. This is a 50.58 percent increase over earnings of $5.18 per…
1 week ago benzinga.com
Procter & Gamble, Western Digital On Deck Thursday As Growth, AI Demand Face Test
Procter & Gamble headlines Thursday’s reports, with investors weighing resilient consumer demand against cost pressures and softer earnings growth. Union Pacific, Lockheed Martin, Valero Energy and…
-
1 week ago benzinga.com
RBC Capital Maintains Outperform on argenx, Lowers Price Target to $1025
RBC Capital analyst Luca Issi maintains argenx (NASDAQ:ARGX) with a Outperform and lowers the price target from $1100 to $1025.
-
1 week ago benzinga.com
argenx SE To Present New Data From Phase 3 Study Evaluating VYVGART Hytrulo In Patients With Autoimmune Myositis, Focused On IMNM And DM, At ACR Convergence 2026
Results from the global Phase 3 ALKIVIA study, the first registrational study investigating an FcRn blocker in autoimmune myositis, show efgartigimod provides clinically meaningful improvements in…
2 weeks ago globenewswire.com
argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
October 15, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will host a conference call and audio webcast on…
-
2 weeks ago benzinga.com
Wells Fargo Maintains Overweight on argenx, Raises Price Target to $1356
Wells Fargo analyst Derek Archila maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $1355 to $1356.
2 weeks ago businesswire.com
ARGX Investors with $100,000 in Losses Have Opportunity to Join argenx SE Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $ARGX--ARGX Investors with $100,000 in Losses Have Opportunity to Join argenx SE Fraud Investigation with SBS Law.
-
2 weeks ago benzinga.com
Oppenheimer Maintains Outperform on argenx, Lowers Price Target to $1038
Oppenheimer analyst Leland Gershell maintains argenx (NASDAQ:ARGX) with a Outperform and lowers the price target from $1100 to $1038.
3 weeks ago zacks.com
argenx Meets Primary Endpoint in Phase II Celiac Disease Study
ARGX's FB102 achieves its primary endpoint in a phase II celiac disease study, paving the way for late-stage development despite a nearly 12% stock drop.
-
3 weeks ago benzinga.com
Evercore ISI Group Maintains Outperform on argenx, Lowers Price Target to $1078
Evercore ISI Group analyst Gavin Clark-Gartner maintains argenx (NASDAQ:ARGX) with a Outperform and lowers the price target from $1175 to $1078.
3 weeks ago zacks.com
ARGX Stock Down on Stopping Late-Stage Autoimmune Disease Study
argenx shares tumble 12% after discontinuing its late-stage Sjogren's disease study, while positive FB102 data in celiac disease offer a contrasting pipeline development.
3 weeks ago seekingalpha.com
argenx: The Sjögren's Selloff Looks Overdone
argenx shares fell after halting its Phase 3 Sjögren's trial, but the selloff appears to overstate the lost opportunity. VYVGART franchise remains robust, driving strong cash generation and funding…
-
3 weeks ago benzinga.com
Baird Maintains Neutral on argenx, Lowers Price Target to $823
Baird analyst Colleen Kusy maintains argenx (NASDAQ:ARGX) with a Neutral and lowers the price target from $932 to $823.
3 weeks ago benzinga.com
$100 Invested In argenx 5 Years Ago Would Be Worth This Much Today
argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 10.42% on an annualized basis producing an average annual return of 22.71%. Currently, argenx has a market capitalization of…
3 weeks ago prnewswire.com
argenx Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into argenx (ARGX)
ARGX share price fell sharply after a futility finding resulted in the discontinuation of a pending Phase 3 trial. SueWallSt notifies investors of a pending investigation.
3 weeks ago zacks.com
HALO Wins Court Order Blocking Merck's Keytruda SC in Europe
Halozyme wins a Dutch court order blocking Merck's Keytruda SC in eight European markets, strengthening its position in the patent dispute.
3 weeks ago proactiveinvestors.com
argenx shares drop after trial of Vyvgart in Sjögren's disease is halted
Shares in argenx SE (NASDAQ:ARGX) fell nearly 15% in New York on Thursday after it discontinued a late-stage trial of its drug Vyvgart in Sjögren's disease. Sjögren's disease is a chronic autoimmune…
3 weeks ago benzinga.com
Crude Oil Gains 5%; PepsiCo Posts Upbeat Q3 Earnings
U.S. stocks fell Thursday as Nasdaq slid 150+ points; energy rallied, healthcare dropped. PepsiCo beat estimates but cut FY26 outlook; oil jumped 5%.
3 weeks ago benzinga.com
Argenx Halts Phase 3 Study in Rare Disease Following Futility Analysis
Argenx SE (NASDAQ:ARGX) on Thursday delivered mixed clinical updates, announcing positive Phase 2 trial results for one experimental pipeline candidate alongside the failure of a Phase 3 study for…
3 weeks ago benzinga.com
Argenx Halts Phase 3 Study in Rare Disease Following Futility Analysis
Argenx announced Phase 2 success for FB102 in celiac disease while halting its Phase 3 UNITY study in Sjögren's disease for futility.
3 weeks ago benzinga.com
Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 450 points on Thursday.
3 weeks ago benzinga.com
Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. stock futures fell, with Dow futures down 450 points. Argenx sank 8.7% after a Sjögren’s trial was halted for futility; others also slid.
3 weeks ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Profound Medical (NASDAQ:PROF) shares moved upwards by 21.5% to $6.9 during Thursday's pre-market session. The company's market cap stands at $207.5 million. Haemonetics (NYSE:HAE) stock…
3 weeks ago reuters.com
Argenx discontinues Vyvgart study in Sjögren's disease, shares tumble
Argenx said on Thursday it had discontinued a late-stage study of its efgartigimod drug in adults with Sjögren's disease, an autoimmune condition that damages the glands producing tears and saliva,…
3 weeks ago wsj.com
Argenx Shares Plunge After Autoimmune-Disease Trial Halt
The stock was down 18%, wiping out year-to-date gains after the biotech stopped a late-stage clinical trial of its Vyvgart drug due to lack of efficacy.
3 weeks ago benzinga.com
Why Applied Digital Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Applied Digital shares rise after Q1 revenue and loss beat estimates; Xiao-I and iPower lead gainers, while China SXT and Medicus Pharma fall.
-
3 weeks ago benzinga.com
Argenx's FB102 Meets Primary Endpoint In Phase 2 Celiac Disease Study Versus Placebo With No New Safety Signals; Company Will Advance First-In-Class CD122 Inhibitor Into Phase 3 Development
Study met primary endpoint of change from baseline in the ratio of Vh:Cd (p=0.0176)First Phase 2 evidence that blocking CD122 can prevent gluten-induced intestinal damage in people living with celiac…
3 weeks ago globenewswire.com
argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
Study met primary endpoint of change from baseline in the ratio of Vh:Cd (p= 0.0176 ) First Phase 2 evidence that blocking CD122 can prevent gluten-induced intestinal damage in people living with…
-
3 weeks ago benzinga.com
Halozyme Therapeutic Expands Collaboration, License Deal With Argenx Over Development, Commercialization Of ENHANCE With Two Additional Targets
Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced that it has expanded its global collaboration and license agreement with argenx to develop and commercialize
1 month ago benzinga.com
Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today
argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 14.22% on an annualized basis producing an average annual return of 26.19%. Currently, argenx has a market capitalization of…
-
1 month ago benzinga.com
Wedbush Reiterates Outperform on argenx, Maintains $1150 Price Target
Wedbush analyst David Nierengarten reiterates argenx (NASDAQ:ARGX) with a Outperform and maintains $1150 price target.
-
1 month ago benzinga.com
Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today
argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 13.58% on an annualized basis producing an average annual return of 24.86%. Currently, argenx has a market capitalization of…
-
1 month ago benzinga.com
Wedbush Reiterates Outperform on argenx, Maintains $1150 Price Target
Wedbush analyst David Nierengarten reiterates argenx (NASDAQ:ARGX) with a Outperform and maintains $1150 price target.
-
2 months ago benzinga.com
Morgan Stanley Maintains Overweight on argenx, Raises Price Target to $1250
Morgan Stanley analyst Sean Laaman maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $1230 to $1250.